Print
Email
Print Edition StoriesTuesday, February 9, 2010
Slater puts $500K into wound startup CytoSolv
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
CytoSolv Inc., a biotech startup in Providence, R.I., has taken in $500,000 in seed-stage funding from the Slater Technology Fund, Rhode Island’s state-backed venture capital fund.
Founded by Brown University researchers Moses Goddard and Christopher Thanos, CytoSolv is developing proprietary technology to address wound healing, initially targeting diabetic ulcers. The company’s technology is based on research that will be published in the upcoming issue of scientific journal Cell Transplantation, according to officials.
Specifically, CytoSolv is developing technology that involves a mixture of wound-healing factors derived from porcine choroid plexus (CP), a key component of the blood brain barrier, which naturally secretes a variety of proteins into the cerebrospinal fluid of pigs. The company has teamed up with Living Cell Technologies Ltd. of Australia and New Zealand, which has given CytoSolv access to source material from a genetically pure swineherd that has been isolated on a remote island off the southern coast of New Zealand.
CytoSolv has moved to 117 Chapman St. in Providence, where the office and laboratory facilities were built by Belvoir Properties.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
